Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 12/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11011526 | 0.96 | NOD1 (0.64) | NOD1SLC6A5EPHX2GLP1R | |
| SCHEMBL7135086 | 0.96 | NOD1 (0.64) | NOD1SLC6A5EPHX2GLP1R | |
| SCHEMBL2344383 | 0.95 | NOD1 (0.66) | NOD1SLC6A5EPHX2GLP1R | |
| SCHEMBL539142 | 0.95 | NOD1 (0.66) | NOD1SLC6A5EPHX2GLP1R | |
| SCHEMBL2340732 | 0.95 | NOD1 (0.66) | NOD1SLC6A5EPHX2GLP1R | |
| SCHEMBL359523 | 0.95 | NOD1 (0.66) | NOD1SLC6A5EPHX2GLP1R | |
| SCHEMBL19499060 | 0.95 | NOD1 (0.66) | NOD1SLC6A5EPHX2GLP1R | |
| SCHEMBL2343614 | 0.95 | NOD1 (0.66) | NOD1SLC6A5EPHX2GLP1R | |
| SCHEMBL11102825 | 0.95 | NOD1 (0.66) | NOD1SLC6A5EPHX2GLP1R | |
| SCHEMBL11102827 | 0.95 | NOD1 (0.66) | NOD1SLC6A5EPHX2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AADAT, KYNU, PNISR | NOD1 3917/4885SLC6A5 3122/4885EPHX2 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.